{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:18:52Z","timestamp":1783448332286,"version":"3.55.0"},"reference-count":22,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":165,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Guard Therapeutics"},{"name":"Antaros Medical AB"},{"name":"Swedish Cancer Society"},{"name":"the ALF agreement"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate whether early renal and bone marrow effects \u2013 previously identified through laboratory tests \u2013 can be detected using MRI and 18F-FLT PET-MR in neuroendocrine tumor patients treated with 177Lu-DOTATATE. Despite known early changes, precise clinical tools to monitor these effects remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ten patients with metastatic NETs, scheduled to initiate at least four treatment cycles of 177Lu-DOTATATE, were included. MRI was performed at all designated treatment time points, whereas F-FLT PET was acquired only at baseline and on day 2 following treatment initiation. Bone marrow (BM) fat conversion, proliferative activity, and renal effects were studied with MRI and 18F-FLT PET-MR. Laboratory tests for hematology and kidney and liver function were taken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six patients completed the full imaging protocol with MRI, of whom 18F-FLT PET-MR examinations were performed in two patients. All subjects demonstrated increased BM fat content during the study interval, with a mean of +12.8%. The magnitude of the increase varied substantially, from +3.8% to +23.5%. There was a strong correlation between increased BM fat content and reduced peripheral blood cell counts. Decreased FLT uptake was found on day 2 after treatment. An increase in renal arterial flow and parenchymal volume was detected during the first week after treatment. No sustained renal effects were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The hematological effects observed with laboratory tests after 177Lu-DOTATATE treatment in neuroendocrine tumor patients can be detected by MRI as an increase in bone marrow fat content. This finding was supported by decreased FLT uptake on 18F-FLT PET-MR, indicating decreased bone marrow cell proliferation. MRI can also identify renal effects associated with this therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-25-0036","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:38:02Z","timestamp":1771504682000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["MRI and 18F-fluorothymidine PET-MR for the early evaluation of renal and bone marrow effects in 177Lu-DOTATATE therapy"],"prefix":"10.1530","volume":"6","author":[{"given":"Angeliki","family":"Dimopoulou Creusen","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvin","family":"Johansson","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hagmar","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-969X","authenticated-orcid":true,"given":"H\u00e5kan","family":"Ahlstr\u00f6m","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4854-6075","authenticated-orcid":true,"given":"Dan","family":"Granberg","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026070713575986000_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr Cancer Ther Rev"},{"key":"2026070713575986000_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/CMAR.S125864","article-title":"Considering renal risk while managing cancer","volume":"9","author":"Shahinian","year":"2017","journal-title":"Cancer Manag Res"},{"key":"2026070713575986000_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ckj\/sfaa127","article-title":"Preventive strategies for acute kidney injury in cancer patients","volume":"14","author":"Cosmai","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026070713575986000_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/jmri.25769","article-title":"Quantitative MRI and spectroscopy of bone marrow","volume":"47","author":"Karampinos","year":"2018","journal-title":"J Magn Reason Imaging"},{"key":"2026070713575986000_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4274\/mirt.22931","article-title":"Proliferative and glycolytic assessment of the whole-body bone marrow compartment","volume":"24","author":"Goryawala","year":"2015","journal-title":"Mol Imaging Radionucl Ther"},{"key":"2026070713575986000_bib6","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177 Lu-DOTATATE: the IEO phase I\u2013II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713575986000_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713575986000_bib8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026070713575986000_bib9","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026070713575986000_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713575986000_bib11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J Nucl Med"},{"key":"2026070713575986000_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070713575986000_bib13","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomized, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070713575986000_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijrobp.2014.05.041","article-title":"Fat composition changes in bone marrow during chemotherapy and radiation therapy","volume":"90","author":"Carmona","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026070713575986000_bib15","doi-asserted-by":"crossref","first-page":"e033923","DOI":"10.1136\/bmjopen-2019-033923","article-title":"HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol","volume":"10","author":"Mccafferty","year":"2020","journal-title":"BMJ Open"},{"key":"2026070713575986000_bib16","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1038\/s41375-020-0886-x","article-title":"Adipocytes in hematopoiesis and acute leukemia: friends, enemies, or innocent bystanders?","volume":"34","author":"Zinngrebe","year":"2020","journal-title":"Leukemia"},{"key":"2026070713575986000_bib17","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1210\/jc.2008-2532","article-title":"Increased bone marrow fat in anorexia nervosa","volume":"94","author":"Bredella","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713575986000_bib18","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.3212","article-title":"Bone marrow fat changes after gastric bypass surgery are associated with loss of bone mass","volume":"32","author":"Kim","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2026070713575986000_bib19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1681\/ASN.2010111143","article-title":"Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging","volume":"22","author":"Inoue","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026070713575986000_bib20","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/ar.24260","article-title":"What makes the kidney susceptible to hypoxia?","volume":"303","author":"Evans","year":"2020","journal-title":"Anat Rec"},{"key":"2026070713575986000_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018478","article-title":"Description of a transient proximal tubulopathy induced by amino acids perfusion in peptide receptor radionuclide therapy: a case report","volume":"98","author":"Lenain","year":"2019","journal-title":"Medicine"},{"key":"2026070713575986000_bib22","doi-asserted-by":"crossref","first-page":"W186","DOI":"10.2214\/AJR.09.3106","article-title":"Relation between total renal volume and renal function: usefulness of 3D sonographic measurements with a matrix array transducer","volume":"194","author":"Kim","year":"2010","journal-title":"Am J Roentgenol"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/6\/1\/EO-25-0036.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/6\/1\/EO-25-0036.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0036\/505861\/eo-25-0036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0036\/505861\/eo-25-0036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:58:24Z","timestamp":1783447104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e250036\/75487\/MRI-and-18F-fluorothymidine-PET-MR-for-the-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-25-0036","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e250036"}}